Cargando…
Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
BACKGROUND: To assess efficacy and safety of treatment simplification to co-formulated Rilpivirine/Emtricitabine/Tenofovir (RPV/FTC/TDF) in virologically suppressed patients. MATERIALS AND METHODS: Endpoints of the analysis were: (a) treatment discontinuation of RPV/FTC/TDF for any reasons and (b) o...
Autores principales: | Pinnetti, Carmela, Di Giambenedetto, Simona, Maggiolo, Franco, Lorenzini, Patrizia, Fabbiani, Massimiliano, Tommasi, Chiara, Latini, Alessandra, Ammassari, Adriana, Loiacono, Laura, Sterrantino, Gaetana, Bellagamba, Rita, Boumis, Evangelo, Antinori, Andrea, Zaccarelli, Mauro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International AIDS Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225448/ https://www.ncbi.nlm.nih.gov/pubmed/25397556 http://dx.doi.org/10.7448/IAS.17.4.19812 |
Ejemplares similares
-
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis
por: Zaccarelli, Mauro, et al.
Publicado: (2014) -
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study
por: Latini, Alessandra, et al.
Publicado: (2016) -
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014) -
Poke Not Prod: First Canadian Experience Using Donor-Derived Cell Free DNA to Replace Endomyocardial Biopsy During COVID-19
por: Rodenas-Alesina, E., et al.
Publicado: (2022) -
Place de l’antibiothérapie dans la prise en charge de l’infection au SARS COV2
por: Kalboussi, S., et al.
Publicado: (2022)